References
- Gauld SB, Dal Porto JM, Cambier JC. B cell antigen receptor signaling: roles in cell development and disease. Science 2002;296(5573):1641–1642.
- Davis RE, Ngo VN, Lenz G, et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 2010;463(7277): 88–92.
- Wiestner A. Targeting B-cell receptor signaling for anticancer therapy: the Bruton's tyrosine kinase inhibitor ibrutinib induces impressive responses in B-cell malignancies. J Clin Oncol 2013;31:128–130.
- Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 2013;369:507–516.
- Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 2013;369: 32–42.
- Yasuhiro T, Yoshizawa T, Birkett JT, et al. Ono-4059, a novel Bruton's tyrosine kinase (BTK) inhibitor: synergistic activity in combination with chemotherapy in a abc-DLBCL cell line. Blood 2013;122:5151.
- Salles G, Karlin L, Rule S, et al. A phase I study of the oral BTK inhibitor ono-4059 in patients with relapsed/refractory and high risk chronic lymphocytic leukaemia (cll). Blood 2013;122:676.
- Rule S, Shah N, Salles GA, et al. A phase I study of the oral BTK inhibitor ono-4059 in patients with relapsed/refractory B-cell lymphoma. Blood: ASH Annual Meeting Abstracts. 2013;122:Abstract 4397.
- Dubovsky JA, Flynn R, Du J, et al. Ibrutinib treatment ameliorates murine chronic graft-versus-host disease. J Clin Invest 2014;124: 4867–4876.
- Chen R, Palmer JM, Tsai N-C, et al. Brentuximab vedotin is associated with improved progression-free survival after allogeneic transplantation for Hodgkin lymphoma. Biol Blood Marrow Transplant 2014;20:1864–1868.
- Chen R, Palmer JM, Thomas SH, et al. Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma. Blood 2012;119:6379–6381.
- Garciaz S, Coso D, Peyrade F, et al. Brentuximab vedotin followed by allogeneic transplantation as salvage regimen in patients with relapsed and/or refractory Hodgkin lymphoma. Hematol Oncol 2013;32:187–191.
- Illidge T, Bouabdallah R, Chen R, et al. Allogeneic transplant following brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Leuk Lymphoma 2014;56:703–710.